AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 4934047 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 10 mg and Cyclizine 50 mg combination
Number of subjects: 13
Study 4934047 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 100 mg
Number of subjects: 13
Study 4934047 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug combinations
Number of subjects: 13
Study 30811543 — intervention group
Group type: EXPERIMENTAL
Intervention: Short 6-week modified tai chi course
Number of subjects: 0
Study 31519277 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengzhan Shengmai (DZSM) capsules, 0.36 g, twice daily for 12 months
Number of subjects: 3143
Study 31519277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3143
Study 28650791 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium hypochlorite after acid etching for 60 seconds
Number of subjects: 40
Study 28650791 — intervention group
Group type: EXPERIMENTAL
Intervention: Papain gel after acid etching for 60 seconds
Number of subjects: 40
Study 28650791 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromelain gel after acid etching for 60 seconds
Number of subjects: 40
Study 28650791 — intervention group
Group type: COMPARATOR
Intervention: Control group (37% phosphoric acid etching for 60 seconds)
Number of subjects: 40
Study 26332051 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week shoulder-strength programme with Thera-Band® elastic bands (experimental group)
Number of subjects: 40
Study 26332051 — intervention group
Group type: COMPARATOR
Intervention: Aquatic training (training group)
Number of subjects: 40
Study 26332051 — intervention group
Group type: COMPARATOR
Intervention: Control group (young sedentary male students)
Number of subjects: 40
Study 26332051 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric action at 3.14 rad s(‐1) (experimental group)
Number of subjects: 40
Study 24621936 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 56
Study 24621936 — intervention group
Group type: COMPARATOR
Intervention: Standard CHF therapy (Control)
Number of subjects: 56
Study 21644059 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐3134 25 mg
Number of subjects: 31
Study 21644059 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg
Number of subjects: 31
Study 21644059 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MK‐3134 and Donepezil
Number of subjects: 31
Study 21644059 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine 0.5 mg
Number of subjects: 31
Study 18552277 — intervention group
Group type: EXPERIMENTAL
Intervention: Istradefylline (40 mg daily for 14 days)
Number of subjects: 20
Study 18552277 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (40 mg single dose)
Number of subjects: 20
Study 16731138 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 107
Study 16731138 — intervention group
Group type: COMPARATOR
Intervention: On-pump surgery
Number of subjects: 107
Study 12956494 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular two-implant overdentures
Number of subjects: 60
Study 12956494 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 60
Study 11139103 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (8.1 ng/mL)
Number of subjects: 21
Study 11139103 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (0.68 ng/mL)
Number of subjects: 21
Study 9175819 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DR-shared blood transfusion
Number of subjects: 0
Study 9175819 — intervention group
Group type: COMPARATOR
Intervention: HLA-mismatched transfusion
Number of subjects: 0
Study 8472829 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg budesonide
Number of subjects: 20
Study 8472829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2416423 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin + vinblastine + bleomycin
Number of subjects: 191
Study 2416423 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 191
Study 30153096 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide plus aspirin
Number of subjects: 382
Study 30153096 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 382
Study 27575599 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised audit and feedback (A&F) intervention
Number of subjects: 795
Study 27575599 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised graphical A&F plus written behaviour change message
Number of subjects: 795
Study 27575599 — intervention group
Group type: COMPARATOR
Intervention: Control group (no A&F intervention)
Number of subjects: 795
Study 27575599 — intervention group
Group type: EXPERIMENTAL
Intervention: A&F with health board comparator
Number of subjects: 795
Study 27575599 — intervention group
Group type: EXPERIMENTAL
Intervention: A&F at 0 and 6 months
Number of subjects: 795
Study 24704290 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml aspiration
Number of subjects: 100
Study 24704290 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml aspiration
Number of subjects: 100
Study 24704290 — intervention group
Group type: COMPARATOR
Intervention: 0 ml aspiration (no aspiration)
Number of subjects: 100
Study 22140197 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted gait training (RAGT) using Lokomat
Number of subjects: 67
Study 22140197 — intervention group
Group type: COMPARATOR
Intervention: Over-ground walking training
Number of subjects: 67
Study 22140197 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (RAGT and over-ground walking training)
Number of subjects: 67
Study 20571374 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured computer course on Internet health information retrieval
Number of subjects: 12
Study 20571374 — intervention group
Group type: COMPARATOR
Intervention: Control group (not attending the program)
Number of subjects: 12
Study 17885258 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 7329
Study 17885258 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 7329
Study 16036198 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian multi-needle intervention (LOMNI)
Number of subjects: 35
Study 16036198 — intervention group
Group type: COMPARATOR
Intervention: Step-up ovulation induction treatment with recombinant follicle-stimulating hormone followed by intrauterine insemination for three cycles
Number of subjects: 35
Study 12506332 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin level determinations
Number of subjects: 210
Study 12506332 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine monitoring of digoxin levels
Number of subjects: 210
Study 12506332 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate digoxin level determinations
Number of subjects: 210
Study 9926183 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg i.v. before propofol (2 mg/kg) induction (Group A)
Number of subjects: 175
Study 9926183 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of propofol and metoclopramide (Group B)
Number of subjects: 175
Study 9926183 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide i.v. with rubber tourniquet for 1 min before propofol (Group C)
Number of subjects: 175
Study 9926183 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg (Group D)
Number of subjects: 175
Study 9926183 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group E)
Number of subjects: 175
Study 7770284 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO (100 U/kg/d, 5 days per week)
Number of subjects: 157
Study 2333803 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective/cognitive empathy training program (4 sessions of 1.5 hours each)
Number of subjects: 24
Study 340332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine plus antacid
Number of subjects: 240
Study 340332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine plus dummy antacid
Number of subjects: 240
Study 340332 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet plus antacid
Number of subjects: 240
Study 340332 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 240
Study 340332 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 240
Study 30548106 — intervention group
Group type: COMPARATOR
Intervention: PB-SCS (paresthesia-based stimulation)
Number of subjects: 28
Study 30548106 — intervention group
Group type: EXPERIMENTAL
Intervention: SP-SCS (subperception-based stimulation) - burst program
Number of subjects: 28
Study 30548106 — intervention group
Group type: EXPERIMENTAL
Intervention: SP-SCS (subperception-based stimulation) - 1 kHz program
Number of subjects: 28
Study 28832739 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.03% eye drops t.i.d.
Number of subjects: 16
Study 28832739 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate 4% eye drops t.i.d.
Number of subjects: 16
Study 25461822 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Learning (ML) alone
Number of subjects: 39
Study 25461822 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotics plus Motor Learning (ML)
Number of subjects: 39
Study 25461822 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) plus Motor Learning (ML)
Number of subjects: 39
Study 25461822 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 39
Study 23365053 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine 25 mg
Number of subjects: 30
Study 23365053 — intervention group
Group type: COMPARATOR
Intervention: Intranasal midazolam 2 mg
Number of subjects: 30
Study 21069378 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance athletes (EG)
Number of subjects: 20
Study 21069378 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 20
Study 19584603 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) during treatment
Number of subjects: 10000000
Study 19584603 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) during survivorship
Number of subjects: 10000000
Study 19584603 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) during palliative care
Number of subjects: 10000000
Study 19584603 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 10000000
Study 17969813 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxol + Cisplatin (Tax + Cis)
Number of subjects: 85
Study 17969813 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide + Etoposide + Carboplatin (CEP)
Number of subjects: 85
Study 17969813 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroendocrine differentiation
Number of subjects: 85
Study 17969813 — intervention group
Group type: EXPERIMENTAL
Intervention: No neuroendocrine differentiation
Number of subjects: 85
Study 17969813 — intervention group
Group type: EXPERIMENTAL
Intervention: Tax + Cis group
Number of subjects: 85
Study 17969813 — intervention group
Group type: COMPARATOR
Intervention: CEP group
Number of subjects: 85
Study 15034827 — intervention group
Group type: EXPERIMENTAL
Intervention: New cell-cultured smallpox vaccine
Number of subjects: 350
Study 15034827 — intervention group
Group type: COMPARATOR
Intervention: Live vaccinia virus vaccine
Number of subjects: 350
Study 11685164 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin 70 U/kg
Number of subjects: 40
Study 11685164 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 60 IU/kg
Number of subjects: 40
Study 11685164 — intervention group
Group type: EXPERIMENTAL
Intervention: Both unfractionated heparin and dalteparin
Number of subjects: 40
Study 9922821 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan 6 mg
Number of subjects: 186
Study 9922821 — intervention group
Group type: COMPARATOR
Intervention: Customary treatment
Number of subjects: 186
Study 7998416 — intervention group
Group type: EXPERIMENTAL
Intervention: B subunit-whole cell cholera vaccine (B-WC), 2 or 3 doses
Number of subjects: 0
Study 7998416 — intervention group
Group type: EXPERIMENTAL
Intervention: B subunit-whole cell cholera vaccine (B-WC), 2 doses
Number of subjects: 0
Study 7998416 — intervention group
Group type: EXPERIMENTAL
Intervention: New B subunit-whole cell cholera vaccine (recombinant B subunit)
Number of subjects: 0
Study 7998416 — intervention group
Group type: COMPARATOR
Intervention: Control group (previously unvaccinated)
Number of subjects: 0
Study 3263243 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose corticosteroids (HDC)
Number of subjects: 30
Study 3263243 — intervention group
Group type: COMPARATOR
Intervention: Infused saline (Control)
Number of subjects: 30
Study 29756459 — intervention group
Group type: COMPARATOR
Intervention: Expiratory muscle training
Number of subjects: 31
Study 27506739 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval-walking (IW)
Number of subjects: 10
Study 27506739 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous walking (CW)
Number of subjects: 10
Study 27506739 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10
Study 25609264 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs enriched intravenous fat emulsion (IVFE)
Number of subjects: 99
Study 25609264 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving a lipid emulsion comprised of soybean oil and MCTs
Number of subjects: 99
Study 23875551 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group therapy (4 sessions)
Number of subjects: 30
Study 23875551 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 20177843 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training group
Number of subjects: 71
Study 20177843 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 71
Study 18379396 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg for 4 weeks, then maintained or titrated to 5 or 20 mg at weeks 4 and 8
Number of subjects: 418
Study 18379396 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 418
Study 18379396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study 15685244 — intervention group
Group type: EXPERIMENTAL
Intervention: 74 Gy group
Number of subjects: 126
Study 15685244 — intervention group
Group type: COMPARATOR
Intervention: 64 Gy group
Number of subjects: 126
Study 15685244 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 cm margin group
Number of subjects: 126
Study 15685244 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 cm margin group
Number of subjects: 126
Study 15685244 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 126
Study 12889591 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 0
Study 12889591 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 0
Study 10574413 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan monotherapy started at 75 mg and titrated to 300 mg
Number of subjects: 1006
Study 10574413 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan or irbesartan/hydrochlorothiazide
Number of subjects: 1006
Study 8921578 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg initially, 1 mg every four hours for 24 hours)
Number of subjects: 72
Study 8921578 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin (250 micrograms bolus and continuous infusion of 250 micrograms/h for 24 hours)
Number of subjects: 72
Study 2060544 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (37.5 mg)
Number of subjects: 12
Study 2060544 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (100 mg)
Number of subjects: 12
Study 2060544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6834243 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent control over shock
Number of subjects: 96
Study 6834243 — intervention group
Group type: EXPERIMENTAL
Intervention: No control over shock
Number of subjects: 96
Study 6834243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent control over shock
Number of subjects: 96
Study 6834243 — intervention group
Group type: EXPERIMENTAL
Intervention: High-stress conditions (consistent, no control, intermittent)
Number of subjects: 96
Study 30545649 — intervention group
Group type: EXPERIMENTAL
Intervention: NuCare intervention (self-directed workbook) for 6 weeks
Number of subjects: 89
Study 30545649 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control condition)
Number of subjects: 89
Study 30166329 — intervention group
Group type: EXPERIMENTAL
Intervention: eBEACOPP (escalated doses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone)
Number of subjects: 1005
Study 26218231 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training Group (STG)
Number of subjects: 30
Study 26218231 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 30
Study 24435546 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-enriched mixture (CEM) cement
Number of subjects: 51
Study 24435546 — intervention group
Group type: COMPARATOR
Intervention: Electrosurgery and zinc oxide eugenol (ES/ZOE)
Number of subjects: 51
Study 22452529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 4306
Study 22452529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4306
Study 21166630 — intervention group
Group type: EXPERIMENTAL
Intervention: QVA149 (indacaterol/NVA237) 600/100 microg
Number of subjects: 257
Study 21166630 — intervention group
Group type: EXPERIMENTAL
Intervention: QVA149 (indacaterol/NVA237) 300/100 microg
Number of subjects: 257
Study 21166630 — intervention group
Group type: EXPERIMENTAL
Intervention: QVA149 (indacaterol/NVA237) 150/100 microg
Number of subjects: 257
Study 21166630 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Number of subjects: 257
Study 21166630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 21166630 — intervention group
Group type: EXPERIMENTAL
Intervention: QVA149 (indacaterol/NVA237)
Number of subjects: 257
Study 21166630 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 257
Study 18046975 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril 30-60 mg once daily
Number of subjects: 303
Study 18046975 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5-10 mg once daily
Number of subjects: 303
Study 17592372 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling (IG1)
Number of subjects: 183
Study 17592372 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information (IG2)
Number of subjects: 183
Study 17592372 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal telephone counseling (IG3)
Number of subjects: 183
Study 17592372 — intervention group
Group type: COMPARATOR
Intervention: No counseling (IG0)
Number of subjects: 183
Study 12690593 — intervention group
Group type: EXPERIMENTAL
Intervention: UFOV training of visual processing speed, divided attention, and selective attention
Number of subjects: 97
Study 12690593 — intervention group
Group type: COMPARATOR
Intervention: Traditional computerized visuoperception retraining
Number of subjects: 97
Study 11094308 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) alpha‐2b at a dose of 20 MU/m2/day, 5 days per week for one month, followed by 10 MU/m2 TIW, up to one complete year of therapy
Number of subjects: 1000
Study 11094308 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 1000
Study 9186075 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Well‐Being (QWB) scale
Number of subjects: 1284
Study 9186075 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom Checklist‐90R (SCL‐90R)
Number of subjects: 1284
Study 9186075 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Symptom Form
Number of subjects: 1284
Study 1338896 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet intervention
Number of subjects: 905
Study 1338896 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 905
Study 2413300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous trimazosin (100 mg)
Number of subjects: 6
Study 2413300 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral trimazosin (200 mg)
Number of subjects: 6
Study 2413300 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 6
Study 31185369 — intervention group
Group type: EXPERIMENTAL
Intervention: Loving-kindness meditation (LKM)
Number of subjects: 142
Study 31185369 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM)
Number of subjects: 142
Study 31185369 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 142
Study 28957806 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder flap
Number of subjects: 208
Study 28957806 — intervention group
Group type: COMPARATOR
Intervention: Omission of bladder flap
Number of subjects: 208
Study 27733571 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg
Number of subjects: 0
Study 27733571 — intervention group
Group type: COMPARATOR
Intervention: SC IFN‐β‐1a 44 μg
Number of subjects: 0
Study 24959193 — intervention group
Group type: EXPERIMENTAL
Intervention: Shen-Zhi-Ling oral liquid (SZL)
Number of subjects: 98
Study 24959193 — intervention group
Group type: COMPARATOR
Intervention: Placebo granules
Number of subjects: 98
Study 22399518 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg daily for 6 weeks)
Number of subjects: 30
Study 22399518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20726258 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose booster of HepB
Number of subjects: 103
Study 20726258 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 dose booster of HepB
Number of subjects: 103
Study 20726258 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 different types of HepB (5 microg HepB-Y, 10 microg HepB-Y, 10 microg HepB-CHO, 10 microg HepB-HY) after 3 doses revaccination
Number of subjects: 103